HeadlineShine

Newly listed stock has 27% upside potential! JM Financial issues buy call; Check target price and key triggers

MintNewly listed stock has 27% upside potential! JM Financial issues buy call; Check target price and key triggers
Image: Mint

JM Financial initiated coverage of Symbiotec Pharmalab with a Buy rating and a ₹1,622 target price, implying about 27% upside. It expects new capacity, CDMO and complex injectable growth to lift revenue, EBITDA and profit through FY29.

Summary from Mint

Read the full story on Mint
React

More on Buy

See all →

More business

See all →

Top stories in India

See all →